The stock of Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) last traded at $22.54, up 1.26% from the previous session.
Data from the available sources indicates that Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is covered by 6 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $50.00 and a low of $47.00, we find $48.00. Given the previous closing price of $22.26, this indicates a potential upside of 115.63 percent. AMLX stock price is now -5.77% away from the 50-day moving average and -28.52% away from the 200-day moving average. The market capitalization of the company currently stands at $1.50B.
In total, 0 analysts have assigned it a hold rating, and 6 have given it a buy rating. Brokers who have rated the stock have averaged $48.20 as their price target over the next twelve months.
With the price target enhanced from $45 to $49, Goldman Upgraded its rating from Neutral to Buy for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX).
In other news, FRATES JAMES M, Chief Financial Officer sold 32,500 shares of the company’s stock on May 16. The stock was sold for $875,451 at an average price of $26.94. Upon completion of the transaction, the Chief Financial Officer now directly owns 55,676 shares in the company, valued at $1.25 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 15, Chief Medical Officer Yeramian Patrick D sold 11,965 shares of the business’s stock. A total of $347,358 was realized by selling the stock at an average price of $29.03. This leaves the insider owning 208,417 shares of the company worth $4.7 million. Insiders disposed of 2,582,726 shares of company stock worth roughly $58.21 million over the past 1 year. A total of 22.79% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AMLX stock. A new stake in Amylyx Pharmaceuticals Inc. shares was purchased by MARSHALL WACE, LLP during the first quarter worth $25,678,000. AVIDITY PARTNERS MANAGEMENT LP invested $20,286,000 in shares of AMLX during the first quarter. In the first quarter, ORBIMED ADVISORS LLC acquired a new stake in Amylyx Pharmaceuticals Inc. valued at approximately $18,336,000. LORD, ABBETT & CO. LLC acquired a new stake in AMLX for approximately $5,636,000. POLAR ASSET MANAGEMENT PARTNERS INC. purchased a new stake in AMLX valued at around $3,994,000 in the second quarter.
With an opening price of $22.81 on Friday morning, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) set off the trading day. During the past 12 months, Amylyx Pharmaceuticals Inc. has had a low of $15.80 and a high of $41.93. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.50, and a quick ratio of 7.30. The fifty day moving average price for AMLX is $23.83 and a two-hundred day moving average price translates $31.48 for the stock.
The latest earnings results from Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at $0.02, beating analysts’ expectations of -$0.24 by 0.26. This compares to -$0.93 EPS in the same period last year. For the current quarter, analysts expect AMLX to generate $92.11M in revenue.
Amylyx Pharmaceuticals Inc.(AMLX) Company Profile
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
